Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raxibacumab (Primary)
  • Indications Anthrax; Bacterial infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Human Genome Sciences

Most Recent Events

  • 11 May 2021 Results of a pooled population pharmacokinetics analysis of data from 3 clinical trials (HGS1021-C1063,HGS1021-C1064 and HGS1021-C1069) published in the British Journal of Clinical Pharmacology
  • 17 Dec 2012 Results from this trial supported US FDA approval of raxibacumab for inhalational anthrax
  • 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top